MINK THERAPEUTICS, INC.

MINK THERAPEUTICS, INC. (INKT)

$1.76

-0.12

(-6.38%)

Market is closed - opens 7 PM, 01 Jun 2023

Insights on MINK THERAPEUTICS, INC.

  • Vs SGEN

    In the last 1 year, Seagen Inc has given 45.9% return, outperforming this stock by 28.6%

Performance

  • $1.76
    $1.97
    $1.76
    downward going graph

    0.0%

    Downside

    Day's Volatility :10.66%

    Upside

    10.66%

    downward going graph
  • $0.85
    $4.32
    $1.76
    downward going graph

    51.65%

    Downside

    52 Weeks Volatility :80.3%

    Upside

    59.26%

    downward going graph

Returns

PeriodMINK THERAPEUTICS, INC.Sector (Health Care)Index (Russel 2000)
3 Months
-15.79%
0.7%
-6.8%
6 Months
-32.82%
-8.3%
-6.0%
1 Year
17.33%
-1.9%
-4.6%
3 Years
-85.33%
25.3%
25.9%

Highlights

Market Capitalization
64.7M
Book Value
- $0.13
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-0.76
Wall Street Target Price
7.0
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-69.76%
Return On Equity TTM
-403.66%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-29.3M
Diluted Eps TTM
-0.76
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.74
EPS Estimate Next Year
-0.8
EPS Estimate Current Quarter
-0.24
EPS Estimate Next Quarter
-0.19

Analyst Recommendation

Buy
    90%Buy
    9%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for MINK THERAPEUTICS, INC.(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 297.73%

Current $1.76
Target $7.00

Technicals Summary

Sell

Neutral

Buy

MINK THERAPEUTICS, INC. is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
MINK THERAPEUTICS, INC.
MINK THERAPEUTICS, INC.
61.47%
-32.82%
17.33%
-85.33%
-85.33%
Moderna, Inc.
Moderna, Inc.
-4.27%
-29.63%
-10.94%
105.39%
586.61%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-8.82%
-3.37%
11.63%
22.7%
139.69%
Seagen, Inc.
Seagen, Inc.
-1.74%
61.71%
45.87%
23.07%
217.59%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-6.21%
0.88%
20.1%
12.88%
112.8%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
MINK THERAPEUTICS, INC.
MINK THERAPEUTICS, INC.
NA
NA
NA
-0.74
-4.04
-0.7
0.0
-0.13
Moderna, Inc.
Moderna, Inc.
11.46
11.46
0.0
-1.9
0.27
0.12
0.0
49.12
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
19.72
19.72
9.01
41.59
0.19
0.1
0.0
219.38
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-2.88
-0.23
-0.12
0.0
14.54
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.15
26.15
0.41
14.62
0.26
0.17
0.0
56.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
MINK THERAPEUTICS, INC.
MINK THERAPEUTICS, INC.
Buy
$64.7M
-85.33%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$49.1B
586.61%
11.46
31.77%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$79.5B
139.69%
19.72
33.81%
Seagen, Inc.
Seagen, Inc.
Hold
$36.7B
217.59%
NA
-31.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$83.8B
112.8%
26.15
35.4%

Institutional Holdings

  • Artal Group S A

    0.84%
  • Longbow Finance SA

    0.49%
  • First Republic Inv Mgmt Inc

    0.15%
  • Vanguard Group Inc

    0.14%
  • Geode Capital Management, LLC

    0.07%
  • StoneX Group Inc

    0.05%

Corporate Announcements

  • MINK THERAPEUTICS, INC. Earnings

    MINK THERAPEUTICS, INC.’s price-to-earnings ratio stands at None

    Read More

Company Information

MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next-generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY.

Organization
MINK THERAPEUTICS, INC.
Employees
37
CEO
Dr. Garo H. Armen Ph.D.
Industry
Services

FAQs